Omega Healthcare Investors enters Wednesday with the July 29 earnings print just cleared, options traders at their most bullish in a year, and short sellers unwinding positions into a stock that has re-rated sharply higher.
The bullish options signal documented in Sunday's preview held through the print. The put/call ratio finished at 0.34 — the lowest reading of the past 52 weeks and nearly two standard deviations below its 20-day average of 0.54. That extreme call-side skew is not a one-day aberration: the PCR ran near 0.60 for all of June and the first half of July before breaking decisively lower over the past week. Options traders positioned for upside, and the stock delivered — OHI closed at $51.64, up 2.1% on the week and 7.4% over the past month.
Short positioning has moved in the same direction. Bears have been covering steadily, with short interest falling 6.1% over the past week to 4.4% of the free float — roughly 13.1 million shares. The pace of that retreat accelerated mid-week: the bulk of the weekly decline happened between July 22 and July 24, when shorts shed around 760,000 shares in two sessions. The borrow market reflects no stress on either side. Cost to borrow is at its lowest level in six weeks at 0.36%, down 12% on the week. Availability is extremely loose at over 3,000% — meaning there are roughly thirty shares available to borrow for every one currently lent out. That's a borrow market with essentially no friction for new shorts if sentiment turns, but right now, new shorts aren't showing up.
The Street is divided, and that division is what makes the current price level interesting. OHI at $51.64 is already above the consensus mean price target of $51.26, which technically implies the stock has priced in the average bull case. Recent analyst moves reflect that tension. Barclays initiated with an Underweight rating and a $51 target in early July — a notable negative given the stock was trading well below that level at initiation. Raymond James reinstated at Outperform with a $50 target in June, and UBS, one of the more constructive voices, holds a Buy with a $54 target. The factor scores lean cautiously on earnings quality: the EPS momentum ranks are in the 27th–46th percentile, and forward EPS growth ranks in the 31st percentile. The one standout is the dividend score at the 90th percentile — the income case remains intact, with the forward yield implying roughly 5.3% at current prices. Bulls lean on demographic tailwinds and improving operator coverage ratios in the skilled nursing segment; bears point to Medicaid policy risk and lowered FFO estimates as the ceiling on near-term growth.
Peers tell a more mixed story after the week's close. SBRA and AHR held broadly flat on the week at +1.0% and +0.2% respectively, while CTRE, WELL, LTC, and NHI all finished lower — NHI down 3.2%. OHI's relative outperformance this week is not a sector-wide rising tide. It is specific to this name heading into and out of its earnings print.
The insider picture adds a cautionary note that sits uncomfortably alongside the bullish positioning. CEO C. Taylor Pickett sold 112,500 shares at $47.94 on June 1 — a $5.4 million sale — following a 200,000-share sale at $44.25 in late December 2025. The CEO did buy 20,000 shares in November 2025 near $43, but the more recent and larger disposals represent net selling at progressively higher prices. The 90-day net insider activity is a net sale of roughly 112,500 shares worth $5.4 million. That doesn't invalidate the bullish near-term setup, but it is worth holding alongside the options picture.
With earnings now in the rearview and the stock sitting fractionally above consensus price targets, the key question for the next few sessions is whether the call-heavy options positioning unwinds — and whether the analyst community responds to the print with target upgrades that give the stock fresh room to run.
See the live data behind this article on ORTEX.
Open OHI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
